Expression analysis of the group IIA secretory phospholipase A2 in mice with differential susceptibility to azoxymethane-induced colon tumorigenesis

Carcinogenesis

Volumn 21, Issue 2, 2000, Pages 133-138

  Papanikolaou, Alexandros ^a   Wang, Qian Shu ^a   Mulherkar, Rita ^b   Bolt, Andrew ^a   Rosenberg, Daniel W ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; MESSENGER RNA; PHOSPHOLIPASE A2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; COLON CANCER; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; TIME;

EID: 0033966580     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/21.2.133     Document Type: Article

References (39)

1. Dragani, T.A. and Manenti, G. (1997) Moml leads the pack. Nature Genet., 17, 7-8.
2. Laird, P.W., Jackson-Grusby, L., Fazeli, A., Dickinson, S.L., Jung, W.E., Li, E., Weinberg, R.A. and Jaenisch, R. (1995) Suppression of intestinal neoplasia by DNA hypomethylation. Cell, 81, 197-205.
3. 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809.
4. Dietrich, W.F., Lander, E.S., Smith, J.S., Moser, A.R., Gould, K.A., Luongo, C., Borenstein, N. and Dove, W. (1993) Genetic identification of Mom-I, a major modifier locus affecting Min-induced intestinal multiple neoplasia in the mouse. Cell, 75, 631-639.
5. Min-induced intestinal neoplasia. Cell, 81, 957-966.
6. Kennedy, B.P., Payette, P., Mudgett, J., Vadas, P., Pruzanski, W., Kwan, M., Tang, C., Rancourt, D.E. and Cromlish, W.A. (1995) A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem., 270, 22378-22385.
7. Cormier, R.T., Hong, K.H., Halberg, R.B., Hawkins, T.L., Richardson, P., Mulherkar, R., Dove, W.F. and Lander, E.S. (1997) Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nature Genet., 17, 88-91.
8. Druckrey, H. (1970) Production of colonic carcinomas by 1,2-dialkyhydrazines and azoxyalkanes. In Burdette, W.J. (ed.) Carcinoma of the Colon and Antecedent Epithelium. Thomas Books, Springfield, IL, pp. 267-279.
9. Papanikolaou, A., Wang, Q.-S., Delker, D.A. and Rosenberg, D.W. (1998) Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. Cancer Lett., 130, 29-34.
10. Deschner, E.E., Long, F.C., Hakissian, M. and Hermann, S.L. (1983) Differential susceptibility of AKR, C57BL/6J and CF1 to 1,2-dimethylhydrazine-induced colonic tumor formation predicted by proliferative characteristics of colonic epithelial cells. J. Natl Cancer Inst., 70, 196-198.
11. Cooper, H.K., Buecheler, J. and Kleihues, P. (1978) DNA alkylation in mice with genetically different susceptibility to 1,2-dimethylhydrazine-induced colon carcinogenesis. Cancer Res., 38, 3063-3065.
12. Delker, D.A., Bammler, T.K. and Rosenberg, D.W. (1996) A comparative study of hepatic and colonic metabolic enzymes in inbred mouse lines before and after treatment with the colon carcinogen 1,2-dimethylhydrazine. Drug Metab. Dispos., 24, 408-413.
13. Papanikolaou, A., Shank, R.C., Delker, D.A. and Rosenberg, D.W. (1998) Initial levels of azoxymethane-induced DNA methyl adducts are not predictive of tumor susceptibility in inbred mice. Toxicol. Appl. Pharmacol., 150, 196-203.
14. Potten, C.S., Li, Y.Q., O'Connor, P.J. and Wínton, D.J. (1992) A possible explanation for the differential cancer incidence in the intestine, based on distribution of the cytotoxic effects of carcinogens in the murine large bowel. Carcinogenesis, 13, 2305-2312.
15. Deschner, E.E., Long, F.C. and Hakissian, B.A. (1988) Susceptibility to 1,2-dimethylhydrazine-induced colonic tumors and epithelial cell proliferation characteristics of F1, F2 and reciprocal backcrosses derived from SWR/J and AKR/J parental mouse strains. Cancer, 61, 478-482.
16. Mulherkar, R., Desai, S.J., Rao, R.S., Wagle, A.S. and Deo, M.G. (1991) Expression of enhancing factor gene and its localization in mouse tissues. Histochemistry, 96, 367-370.
17. Gould, K.A., Luongo, C., Moser, A.R., McNeley, M.K., Borenstein, N., Shedlovsky, A., Dove, W.F., Hong, K., Dietrich, W.F. and Lander, E.S. (1996) Genetic evaluation of candidate genes for the Moml modifier of intestinal neoplasia in mice. Genetics, 144, 1777-1785.
18. Mulherkar, R., Rao, R.S., Wagle, A.S., Patki, V. and Deo, M.G. (1993) Enhancing factor, a Paneth cell specific protein from mouse small intestines: predicted amino acid sequence from RT-PCR amplified cDNA and its expression. Biochem. Biophys. Res. Commun., 195, 1254-1263.
19. Diwan, B.A., Meier, H. and Blackman, K.E. (1977) Genetic differences in the induction of colorectal tumors by 1,2-dimethylhydrazine in inbred mice. J. Natl Cancer Inst., 59, 455-458.
20. Diwan, B.A., Dempster, A.M. and Blackman, K.E. (1979) Effects of methylazoxymethanol acetate on inbred mice: influence of genetic factors on tumor induction. Proc. Soc. Exp. Biol. Med., 161, 347-349.
21. Seilhamer, J.J., Pruzanski, W., Vadas, P., Plant, S., Miller, J.A., Kloss, J. and Johnson, L.K. (1989) Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J. Biol. Chem., 264, 5335-5338.
22. Vadas, P., Browning, J., Edelson, J. and Pruzanski, W. (1993) Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J. Lipid Mediat., 8, 1-30.
23. Atsumi, G., Murakami, M., Tajima, M., Shimbara, S., Hara, N. and Kudo, I. (1997) The perturbed membrane of cells undergoing apoptosis is susceptible to type II secretory phospholipase A2 to liberate arachidonic acid. Biochim. Biophys. Acta, 1349, 43-54.
24. Levy, G.N. (1997) Prostaglandin H synthases, nonsteroidal antiinflammatory drugs and colon cancer. FASEB J., 11, 234-247.
25. Alberts, D.S., Hixson, L., Ahnen, D., Bogert, C., Einspahr, J., Paranka, N., Brendel, K., Gross, P.H., Pamukcu, R. and Burt, R.W. (1995) Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J. Cell Biochem., 22 (suppl.), 18-23.
26. Piazza, G.A., Alberts, D.S., Hixson, L.J., Paranka, N.S., Li, H., Finn, T., Bogert, C., Guillen, J.M., Brendel, K., Gross, P.H., Sperl, G., Ritchie, J., Burt, R.W., Ellsworth, L., Ahnen, D.J. and Ramukcu, R. (1997) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57, 2909-2915.
27. Chiu, C.-H., McEntee, M.F. and Whelan, J. (1997) Sulindac causes rapid regression of preexisting tumors in Minl+ mice independent of prostaglandin biosynthesis. Cancer Res., 57, 4267-4273.
28. Ben-Efraim, S. and Bonta, I.L. (1994) Modulation of antitumor activity of macrophages by regulation of eicosanoids and cytokine production. Int. J. Immunopharmacol., 16, 397-399.
29. Nimmrich, I., Friedl, W., Kruse, R., Pietsch, S., Hentsch, S., Deuter, R., Winde, G. and Muller, O. (1997) Loss of the PLA2G2A gene in a sporadic colorectal tumor of a patient with a PLA2G2A germline mutation and absence of PLA2G2A germline alterations in patients with FAP. Hum. Genet., 100, 345-349.
30. Leister, I., Weith, A., Bruderlein, S., Cziepluch, C., Kangwanpong, D., Schlag, P. and Schwab, M. (1990) Human colorectal cancer: high frequency deletions at chromosome 1p35. Cancer Res., 50, 7232-7235.
31. Bomme, L., Heim, S., Bardi, G., Fenger, C., Kronborg, O., Brogger, A. and Lothe, R.A. (1998) Allelic imbalance and cytogenetic deletion of 1p in colorectal adenomas: a target region identified between D1S199 and D1S234. Genes Chromosom. Cancer, 21, 185-194.
32. Tischfield, J.A., Xia, Y.R., Shih, D.M. Klisak, I., Chen, J., Engle, S.J., Siakotos, A.N., Winstead, M.V., Seilhamer, J.J., Allamand, V., Gyapay, G. and Lusis, A.J. (1996) Low-molecular-weight, calcium-dependent phospholipase A2 genes are linked and map to homologous chromosome regions in mouse and human. Genomics, 32, 328-333.
33. Riggins, G.J., Markowitz, S., Wilson, J.K., Vogelstein, B. and Kinzler, K.W. (1995) Absence of secretory phospholipase A2 gene alterations in human colorectal cancer. Cancer Res., 55, 5184-5186.
34. Spirio, L., Kutchera, W., Winstead, M.V. Pearson, B., Kaplan, C., Robertson, M., Lawrence, E., Burt, R.W., Tischfield, J.A., Leppert, M.F., Prescott, S.M. and White, R. (1996) Three secretory phospholipase A2 genes that map to human chromosome 1p35-36 are not mutated in individuals with attenuated adenomatous polyposis coli. Cancer Res., 56, 955-958.
35. Kennedy, B.P., Soravia, C., Moffat, J., Xia, L., Hiruki, T., Collins, S., Gallinger, S. and Bharati, B. (1998) Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenoma from familial adenomatous polyposis patients. Cancer Res., 58, 500-503.
36. 2 in human hepatocellular carcinoma. Biochim. Biophys. Acta, 1226, 201-205.
37. 2 in human breast cancer tissues is closely associated with their malignant potency. Br. J. Cancer, 69, 1166-1170.
38. 2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occurring carcinogen, 1-hydroxyanthraquinone. Cancer Lett., 97, 75-82.
39. Ikegami, T., Matsuzaki, Y., Shoda, J., Kano, M., Hirabayashi, N. and Tanaka, N. (1998) The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett., 134, 129-139.